Memantine is a non-acetyl cholinesterase inhibitor that helps in Alzheimer's disease therapy. The medicine was approved for sale in Europe in 2002 and the United States Food and Drug Administration ...

June 22, 2010 — Forest Laboratories Inc and Merz Pharmaceuticals GmbH announced yesterday they have received approval from the US Food and Drug Administration of an extended-release formulation of ...

Memantine hydrochloride (Namenda; Forest/Merz), which acts to protect neurons against toxicity caused by overactivation of N-methyl-D-aspartate receptors, became the first drug to be approved by the ...

Memantine is approved to treat moderate to severe Alzheimer's disease and other dementias. Evidence suggests that it might also be useful with bipolar disorder, depression, schizophrenia and much more ...

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. announced today that NAMENDA XR (TM) (memantine hydrochloride) once-daily formulation is now available in pharmacies throughout the United States.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced that it intends to continue to market both its NAMENDA® ...

Memantine, a drug approved for Alzheimer’s disease, was associated with significant improvement in social functioning in some children and adolescents with autism spectrum disorder (ASD) without ...